These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 26042542

  • 1. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
    Ravera M, Gabano E, Zanellato I, Bonarrigo I, Alessio M, Arnesano F, Galliani A, Natile G, Osella D.
    J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
    [Abstract] [Full Text] [Related]

  • 2. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 3. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
    Göschl S, Varbanov HP, Theiner S, Jakupec MA, Galanski MS, Keppler BK.
    J Inorg Biochem; 2016 Jul 01; 160():264-74. PubMed ID: 27055943
    [Abstract] [Full Text] [Related]

  • 4. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 5. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB.
    Clin Cancer Res; 2004 Jul 15; 10(14):4661-9. PubMed ID: 15269138
    [Abstract] [Full Text] [Related]

  • 6. Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)(6NH2}2]Cl3(NO3).
    Al-Shuneigat J, Qing Y, Beale P, Fisher K, Huq F.
    Med Chem; 2011 Jan 15; 7(1):1-8. PubMed ID: 21235513
    [Abstract] [Full Text] [Related]

  • 7. Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(iv) prodrugs as potent anticancer agents.
    Deo KM, Sakoff J, Gilbert J, Zhang Y, Aldrich Wright JR.
    Dalton Trans; 2019 Nov 26; 48(46):17228-17240. PubMed ID: 31728483
    [Abstract] [Full Text] [Related]

  • 8. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
    Song Y, Suntharalingam K, Yeung JS, Royzen M, Lippard SJ.
    Bioconjug Chem; 2013 Oct 16; 24(10):1733-40. PubMed ID: 23957697
    [Abstract] [Full Text] [Related]

  • 10. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
    Xu Z, Chan HM, Li C, Wang Z, Tse MK, Tong Z, Zhu G.
    Inorg Chem; 2018 Jul 16; 57(14):8227-8235. PubMed ID: 29943979
    [Abstract] [Full Text] [Related]

  • 11. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
    Zanellato I, Bonarrigo I, Colangelo D, Gabano E, Ravera M, Alessio M, Osella D.
    J Inorg Biochem; 2014 Nov 16; 140():219-27. PubMed ID: 25171667
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands.
    Margiotta N, Savino S, Marzano C, Pacifico C, Hoeschele JD, Gandin V, Natile G.
    J Inorg Biochem; 2016 Jul 16; 160():85-93. PubMed ID: 26775068
    [Abstract] [Full Text] [Related]

  • 13. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.
    Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G.
    Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087
    [Abstract] [Full Text] [Related]

  • 14. Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.
    Zhao Y, Woods JA, Farrer NJ, Robinson KS, Pracharova J, Kasparkova J, Novakova O, Li H, Salassa L, Pizarro AM, Clarkson GJ, Song L, Brabec V, Sadler PJ.
    Chemistry; 2013 Jul 15; 19(29):9578-91. PubMed ID: 23733242
    [Abstract] [Full Text] [Related]

  • 15. Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.
    Tolan D, Gandin V, Morrison L, El-Nahas A, Marzano C, Montagner D, Erxleben A.
    Sci Rep; 2016 Jul 11; 6():29367. PubMed ID: 27404565
    [Abstract] [Full Text] [Related]

  • 16. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
    Savino S, Marzano C, Gandin V, Hoeschele JD, Natile G, Margiotta N.
    Int J Mol Sci; 2018 Jul 14; 19(7):. PubMed ID: 30011897
    [Abstract] [Full Text] [Related]

  • 17. Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione.
    Kostrhunova H, Kasparkova J, Gibson D, Brabec V.
    Mol Pharm; 2010 Dec 06; 7(6):2093-102. PubMed ID: 20936822
    [Abstract] [Full Text] [Related]

  • 18. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M, Perin E, Gabano E, Zanellato I, Panzarasa G, Sparnacci K, Laus M, Osella D.
    J Inorg Biochem; 2015 Oct 06; 151():132-42. PubMed ID: 26277416
    [Abstract] [Full Text] [Related]

  • 19. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and characterization of cyclohexane-1R,2R-diamine-based Pt(iv) dicarboxylato anticancer prodrugs: their selective activity against human colon cancer cell lines.
    Gabano E, Ravera M, Perin E, Zanellato I, Rangone B, McGlinchey MJ, Osella D.
    Dalton Trans; 2019 Jan 02; 48(2):435-445. PubMed ID: 30539948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.